Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Total article views   Abstract views HTML views PDF downloads Totals
8,992 Dovepress* 6,855 1,332+ 1,543 8,187
PubMed Central* 0 805 313 805
Totals 6,855 2,137 1,856 8,992
*Since 29 June 2017
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 0 2

View citations on PubMed Central and Google Scholar